Soheila Rostami, MD
Ophthalmology · Reston, VANPI 1215963517
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,410 of the $73,199 with a category attached, or 83.9%. Galderma Laboratories, L.p. accounts for 94.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $46,233 and has fallen 98.8% since, to $563 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $487.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$69K
- Merz North America, Inc.$2K
- AbbVie$2K
- Amgen$699
- Revance Therapeutics, Inc.$369
- Alcon$115
- plus $29 from 2 others
What the payments were for
- Consulting fees$1,8753%
- Speaking & faculty fees$61,41084%
- Travel & lodging$5,2327%
- Food & beverage$4,6826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 103 | $68,804 |
| Merz North America, Inc. | 13 | $1,612 |
| AbbVie | 3 | $1,572 |
| Amgen(2 entities) | 23 | $699 |
| Revance Therapeutics, Inc. | 5 | $369 |
| Alcon | 1 | $115 |
| Acelrx Pharmaceuticals, Inc. | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,199 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 35 | $322 |
| ErythromycinErythromycin Base | 24 | $213 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $48 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Reston
- Andrew SiegelReston$12K
- Jacqueline GriffithsReston$8K
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.